Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAALAD2 | Q9Y3Q0 | 3/20 | 0.69 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.56 |
| ▸ | YARS1 | P54577 | 2/20 | 0.54 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.52 |
| ▸ | ENPEP | Q07075 | 2/20 | 0.50 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.49 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | MME | P08473 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11032575 | 1.00 | NAALAD2 (0.69) | NAALAD2SLC7A5YARS1FOLH1ENPEP | |
| SCHEMBL6378283 | 0.97 | NAALAD2 (0.66) | NAALAD2SLC7A5YARS1FOLH1ENPEP | |
| SCHEMBL29538675 | 0.97 | NAALAD2 (0.66) | NAALAD2SLC7A5YARS1FOLH1ENPEP | |
| SCHEMBL11886066 | 0.97 | NAALAD2 (0.66) | NAALAD2SLC7A5YARS1FOLH1ENPEP | |
| SCHEMBL29649767 | 0.96 | NAALAD2 (0.68) | NAALAD2SLC7A5YARS1FOLH1ENPEP | |
| SCHEMBL38650819 | 0.95 | NAALAD2 (0.67) | NAALAD2SLC7A5YARS1FOLH1ENPEP | |
| SCHEMBL29393258 | 0.95 | NAALAD2 (0.67) | NAALAD2SLC7A5YARS1FOLH1ENPEP | |
| SCHEMBL29418370 | 0.95 | NAALAD2 (0.67) | NAALAD2SLC7A5YARS1FOLH1ENPEP | |
| Tyrosine SCHEMBL1495262 | 0.94 | NAALAD2 (0.64) | NAALAD2SLC7A5YARS1FOLH1ENPEP | |
| SCHEMBL30317559 | 0.93 | NAALAD2 (0.60) | NAALAD2SLC7A5YARS1FOLH1ENPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026088246-A1 | METHOD FOR PRODUCING LOW-MOLECULAR-WEIGHT COMPOUND | ＮＴＴ株式会社 | 2026-04-30 | — | — | WO | claimed |
| CN-119757602-A | Biomarker and kit for distinguishing chronic hepatitis B, liver cancer and liver cirrhosis | 厦门市迈理奥科技有限公司 | 2025-04-04 | — | — | CN | claimed |
| CN-117298113-A | Application of tenapanol and liposome targeted M2 macrophage thereof in antitumor drugs | 东南大学 | 2023-12-29 | — | — | CN | claimed |
| CN-115047120-B | Method for analyzing and detecting dansyl chloride derivative of dipeptide substances in white spirit Daqu | 贵州茅台酒股份有限公司 | 2023-08-29 | — | — | CN | claimed |
| WO-2023120844-A1 | COMPOSITION FOR MASS PROLIFERATING NATURAL KILLER CELLS, COMPRISING NOVEL PEPTIDE, AND METHOD FOR MASS PROLIFERATING NATURAL KILLER CELLS BY USING SAME | 엔케이젠 주식회사 | 2023-06-29 | — | — | WO | claimed |
| US-11576946-B2 | Peptidyl inhibitors of calcineurin-NFAT interaction | OHIO STATE INNOVATION FOUNDATION (US) | 2023-02-14 | — | — | US | claimed |
| CN-115047120-A | Dansyl chloride derivatization method for analyzing and detecting dipeptide substances in white spirit Daqu | 贵州茅台酒股份有限公司 | 2022-09-13 | — | — | CN | claimed |
| CN-114984255-A | Radionuclide-labeled PSMA-alpha v beta 3 double-target couplet and application thereof | 苏州大学 | 2022-09-02 | — | — | CN | claimed |
| JP-59034893-A | — | — | None | — | — | JP | disclosed |
| WO-2026107097-A1 | SELF-IMMOLATIVE LINKERS AND CONJUGATES THEREOF | ENLAZA THERAPEUTICS, INC. (US) | 2026-05-21 | — | — | WO | disclosed |
| WO-2026088246-A1 | METHOD FOR PRODUCING LOW-MOLECULAR-WEIGHT COMPOUND | ＮＴＴ株式会社 | 2026-04-30 | — | — | WO | disclosed |
| US-20260042858-A1 | Modified IgG1 Fc Domains and Anti-CD40 Domain Antibody Fusions Therewith | BRISTOL-MYERS SQUIBB COMPANY (US) | 2026-02-12 | — | — | US | disclosed |
| US-20250326814-A1 | MODIFIED OXYNTOMODULIN AND METHODS OF USE THEREOF | OPKO BIOLOGICS LTD. (IL) | 2025-10-23 | — | — | US | disclosed |
| CN-120193029-A | Method for synthesizing chiral 2, 6-dimethyl-1-aminoindene serving as pesticide intermediate | 江苏扬农化工股份有限公司 | 2025-06-24 | — | — | CN | disclosed |
| US-5036052-A | Containing a dipeptide of tryptophan and alanine or lecine and no stabilizer; discoloration inhibition | MORISHITA PHARMACEUTICAL CO., LTD. (JP) | 1991-07-30 | — | — | US | disclosed |
| EP-0347890-A1 | Amino acid nutrient compositions | Roussel Morishita Co., Ltd. (JP) | 1989-12-27 | — | — | EP | disclosed |
| US-4508740-A | Tabletted beverage composition containing dipeptide sweetener and process therefore | GENERAL FOODS CORPORATION (US) | 1985-04-02 | — | — | US | disclosed |
| JP-S5934893-A | PREPARATION OF L-PHENYLALANINE BY FERMENTATION | AJINOMOTO CO INC | 1984-02-25 | — | — | JP | disclosed |
| US-4277464-A | ANTICARIES AGENTS | GENERAL FOODS CORPORATION (US) | 1981-07-07 | — | — | US | disclosed |
| JP-S05934893-A | — | — | 0001-01-01 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250326814-A1 | MODIFIED OXYNTOMODULIN AND METHODS OF USE THEREOF | OGFRL1, OXGR1, THOP1 | NAALAD2 3714/4885SLC7A5 4582/4885YARS1 1686/4885 |
| US-20260042858-A1 | Modified IgG1 Fc Domains and Anti-CD40 Domain Antibody Fusions Therewith | CD40LG, CD40, FCGR1A | NAALAD2 2582/4885SLC7A5 2470/4885YARS1 135/4885 |
| US-11576946-B2 | Peptidyl inhibitors of calcineurin-NFAT interaction | CHP1, NFATC1, PPP3R1 | NAALAD2 844/4885SLC7A5 3504/4885YARS1 146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.